Skip to main content

and
  1. Article

    Open Access

    Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression

    Immunotherapy has shown efficacy in relapsed multiple myeloma (MM). However, these therapies may depend on a functional tumor immune microenvironment (iTME) for their efficacy. Characterizing the evolution of ...

    Alissa Visram, Surendra Dasari, Emilie Anderson, Shaji Kumar in Blood Cancer Journal (2021)

  2. Article

    Open Access

    The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant

    Upfront autologous stem cell transplant (ASCT) is the standard of care for newly diagnosed multiple myeloma (MM) patients. However, relapse is ubiquitous and therapy-related myeloid neoplasms (t-MN) post-ASCT ...

    Saurabh Zanwar, Eapen K. Jacob, Carl Greiner, Kevin Pavelko in Blood Cancer Journal (2023)